Currently, the European Research Initiative for CLL (ERIC) recommends an enlarged panel of monoclonal antibodies (including CD43, CD79b, CD81, CD200, CD10, and ROR1) for the initial characterization, differential diagnosis and follow up of minimal residual disease [21,22]. This evidence concerns the gene CD79B and B-cell chronic lymphocytic leukemia.